SFBC INTERNATIONAL SEES CONTINUED GROWTH IN SALES/EARNINGS.(Brief
Article)(Statistical Data Included)
SFBC International, Inc. (Nasdaq:SFCC), Miami, a rapidly expanding
provider of specialized, outsourced drug development research services
for the pharmaceutical and biotechnology industries, . . .
MEDICIS REPORTS RECORD 4TH QTR/FISCAL YEAR RESULTS.(Medicis
Pharmaceutical Corp.)(Brief Article)(Statistical Data Included)
Medicis Pharmaceutical Corporation (NYSE:MRX), Scottsdale, Ariz.,
has announced fiscal 2001 net income of $51.9 million, or $1.64 per
diluted share, absent the first quarter tax-effected special . . .
CANDELA REPORTS NET INCOME OF $1.1 MILLION FOR 4TH QTR.(Brief
Article)(Statistical Data Included)
Candela Corporation (NASDAQ:CLZR), Wayland, Mass., has reported
results for the fiscal year-end and the quarter ending June 30, 2001.
The company reported that revenues for the quarter were . . .
ENZON REPORTS 127% INCREASE IN 4TH QTR REVENUES.(Brief
Article)(Statistical Data Included)
Enzon, Inc. (NASDAQ:ENZN), Piscataway, N.J., has reported net
income of $3.3 million or $0.08 per diluted share for the fourth quarter
of fiscal year (FY) ended June 30, 2001, as compared to a net . . .
CELL PATHWAYS REPORTS DECREASED NET LOSS FOR SECOND
QTR.(2001)(Brief Article)(Statistical Data Included)
Cell Pathways, Inc. (Nasdaq:CLPA), Horsham, Pa., has reported
financial results for the second quarter and six months ended June 30,
2001.
For the second quarter ended June 30, 2001, the company . . .
ABGENIX REPORTS NET LOSS OF $14.8 MILLION FOR 2ND
QTR.(2001)(Brief Article)(Statistical Data Included)
Abgenix, Inc. (NASDAQ:ABGX), Fremont, Calif., has reported a net
loss of $14.8 million or $0.17 per share for the quarter ended June 30,
2001, compared to a net loss of $2.4 million or $0.03 per . . .
DIACRIN REPORTS 2ND QTR NET LOSS OF $1.3 MILLION.(2001)(Brief
Article)(Statistical Data Included)
Diacrin, Inc. (Nasdaq:DCRN), Charlestown, Mass., has reported
financial results for the second quarter and six months ended June 30,
2001. Net loss for the quarter was $1.3 million, or $.07 per . . .
CEPHEID REPORTS NET LOSS OF $4.1 MILLION FOR 2ND
QTR.(2001)(Statistical Data Included)
Cepheid (Nasdaq: CPHD), Sunnyvale, Calif., developer of
accelerated, integrated DNA testing systems, has announced financial
results for the quarter and six months ended June 30, 2001. . . .
CERUS REPORTS INCREASED NET LOSS FOR SECOND QTR.(2001)(Brief
Article)(Statistical Data Included)
Cerus Corporation (Nasdaq:CERS), Concord, Calif., has announced
results for the second quarter ended June 30, 2001.
The net loss for the second quarter was $12.0 million, or $0.80 per
share, . . .
GENENTECH REPORTS 33% INCREASE IN PRODUCT SALES FOR 2ND
QTR.(Statistical Data Included)
Genentech, Inc. (NYSE:DNA), South San Francisco, has announced a
28 percent increase in net income and a 27 percent increase in earnings
per share(1) driven by a 33 percent increase in product . . .
SONUS REPORTS 2ND QTR. NET LOSS OF $1.7 MILLION.(Brief
Article)(Statistical Data Included)
Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS), Bothell, Wash., has
announced financial results for the second quarter ended June 30, 2001.
The company reported a net loss of $1.7 million, or $0.18 . . .
IMMUDYNE REPORTS 20% INCREASE IN REVENUES FOR 3RD QTR.(Brief
Article)(Statistical Data Included)
ImmuDyne Inc., a Texas-based nutraceuticals company specializing
in dietary supplements and skin care cosmetics, has announced results
for the third quarter ending May 31, 2001. Revenues for the . . .
MAGNA-LAB REPORTS FISCAL QTR. NET LOSS OF $847,000.(Brief
Article)(Statistical Data Included)
Magna-Lab Inc. (OTCBB: MAGLA), Syosset, N.Y. has announced its
results for the fiscal quarter ended May 31, 2001. The company also
noted that it is continuing to move forward with . . .
PSS WORLD MEDICAL REPORTS 4TH QTR NET LOSS OF $9.7 MILLION.(Brief
Article)(Statistical Data Included)
PSS World Medical, Inc., Jacksonville, Fla has announced unaudited
results for the fourth fiscal quarter and fiscal year ended March 31,
2001.
For the three months ended March 31, 2001, net . . .
MICROBIX REPORTS 104% RISE IN SALES AND PROFITABILITY.(Brief
Article)(Statistical Data Included)
Microbix Biosystems Inc. (TSE:MBX), Toronto, has reported a 104%
rise in sales for the first half of fiscal 2001 and earnings of $0.01
per share, its growth continuing in each of the last two . . .
VIVENTIA REPORTS DECREASE IN NET LOSS FOR QUARTER.(Brief
Article)(Statistical Data Included)
Viventia Biotech Inc. (TSE:NVO.), Toronto, has announced the
financial results for the three months ended March 31, 2001.
A net loss of $1,952,000 or $0.01 per share compared with a net
loss of . . .
ALKERMES REPORTS BIG DECREASE IN NET LOSS FOR FISCAL YEAR.(Brief
Article)(Statistical Data Included)
Alkermes, Inc. (NASDAQ:ALKS), Cambridge, Mass., has reported that
the net loss for the fiscal year ended March 31 2001 was $16.9 million
as compared to a net loss of $68.0 million in the prior . . .
ALLERGAN REPORTS FIRST QTR. 8.8% INCREASE IN WORLDWIDE
SALES.(broken down by various product lines)(Statistical Data
Included)
Allergan, Inc. (NYSE:AGN), Irvine, Calif., has announced worldwide
sales increased by 8.8 percent or $33.0 million over the first quarter
last year, at constant currency rates. Including the . . .
FIRST QTR. REVENUES AND NET INCOME UP FOR THERAGENICS.(Brief
Article)(Statistical Data Included)
Theragenics Corporation (NYSE: TGX), the Buford, Georgia-based
cancer treatment producer, has announced revenue and earnings for the
first quarter ending March 31, 2001.
Revenues for the quarter . . .
HYCOR BIOMEDICAL REPORTS 7TH CONSECUTIVE PROFITABLE QTR.(Brief
Article)(Statistical Data Included)
Hycor Biomedical Inc. (NASDAQ:HYBD), Garden Grove, Calif., has
reported results for first quarter 2001.
Sales for the three months ended March 31, 2001, were $4,280,000,
compared with sales of . . .
|
|